EUnetHTA-EMA April Meeting – minutes now available
We are pleased to publish the minutes for the EUnetHTA-EMA Bilateral meeting held online on 28 April, 2021. This meeting concluded the EMA/EUnetHTA work plan 2017-2021, and attendees celebrated the strengthening of successful collaboration through more than a decade of joint work. Access here: EUnetHTA-EMA Bilateral minutes – 28 April 2021
PTRCR20 – Bamlanivimab for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the fourth pharmaceutical Rapid Collaborative Review (PTRCR20) published by EUnetHTA. In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of bamlanivimab alone and bamlanivimab plus etesevimab combination for the treatment of confirmed COVID-19 in patients aged 12 years and older that do not require supplemental oxygen for […]
PTJA17 – Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD) – project plan now available
The final project plan of the relative effectiveness assessment of ‘Elivaldogene autotemcel (eli-cel) for treatment of cerebral adrenoleukodystrophy (CALD)’ is now available for access. The final assessment report will be published on 18 August, 2021. Below is the documentation provided by the Joint Assessment Authoring Team. PTJA17 – Final Project Plan
Engaging Stakeholder in Joint Action 3 – now available for access
As Joint Action 3 (JA3) comes to a close, an overview of stakeholder interaction has been prepared that focusses on who our stakeholders are, the product-related progress we have made, and all related stakeholder activities through JA3. Access here: Engaging Stakeholders in Joint Action 3
PTRCR19 – REGN-COV2 for the treatment of COVID-19 Rapid Collaborative Review- Final Rapid Collaborative Review now available.
This is the third pharmaceutical Rapid Collaborative Review (PTRCR19) published by EUnetHTA. This report describes REGN-COV2 for the treatment of COVID-19 patients. In March 2021, after an Article 5(3) review the European Medicines Agency (EMA) endorsed the use of REGN-COV2 for the treatment of confirmed COVID-19 in patients aged 12 years and older that do […]
